China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2020
October 2020
Section I. Important Notice
Board of Directors Supervisory Committee all directors supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements misleading statements or important omissions carried in this report
and shall take all responsibilities individual and/or joint for the reality
accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third
Quarter Report of the Company in person.Lin Zhaoxiong person in charge of the Company head of the accounting works
Gu Guolin and Wang Ying accounting body principals (accountant in charge)
hereby confirm that the Financial Report of the Third Quarterly Report is
authentic accurate and complete.Section II. Basic information of Company
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data or not
√ Yes □No
Cause of retroactive adjustment or restatement
Enterprises combined under the same control
Current period-end
Period-end of last year Increase/decrease
Before adjustment After adjustment After adjustment
Total assets (RMB) 42013200732.51 33520609123.67 34028843214.20 23.46%
Net assets attributable to
shareholders of listed company
(RMB)
13554151733.76 12806410865.92 12911140435.88 4.98%
Current
period
Same period of last
year
Increase/d
ecrease in
compariso
n with
same
period of
last year
Year-begin
to end of
the Period
Same period of last
year
Increase/d
ecrease in
compariso
n with
year-begin
to
period-end
of last
year
Before
adjustment
After
adjustment
After
adjustment
Before
adjustment
After
adjustment
After
adjustmen
t
Operating revenue (RMB)
15710564
937.11
13647793
431.64
13824236
956.99
13.65%
42880505
125.63
38875940
809.07
3942343
5772.29
8.77%
Net profit attributable to
shareholders of the listed company
(RMB)
35413416
5.83
31131070
6.52
31025359
2.48
14.14%
99758574
6.42
96214406
6.92
9594080
07.03
3.98%
Net profit attributable to
shareholders of the listed company
after deducting non-recurring gains
and losses (RMB)
35431145
3.14
30336528
0.52
30336528
0.52
16.79%
98132847
2.59
94306572
8.47
9430657
28.47
4.06%
Net cash flow arising from
operating activities (RMB)
54514314
2.89
-9079542
0.13
-8036084
0.58
778.37%
1983347
186.24
1072962
161.22
1058793
280.31
87.32%
Basic earnings per share 0.83 0.74 0.72 15.28% 2.33 2.25 2.24 4.02%
(RMB/Share)
Diluted earnings per share
(RMB/Share)
0.83 0.74 0.72 15.28% 2.33 2.25 2.24 4.02%
Weighted average ROE 2.65% 2.53% 2.50%
0.15
percentage
points up
7.56% 7.94% 7.85%
0.29
percentage
points
decline
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Item
Amount from year-begin to
end of the Period
Note
Gains/losses from the disposal of non-current asset (including the
write-off that accrued for impairment of assets)
6670438.32
Mainly for the income from
off-lease stores.Governmental subsidy reckoned into current gains/losses (not
including the subsidy enjoyed in quota or ration according to
national standards which are closely relevant to enterprise’s
business)
36307932.91
Mainly affected by the
COVID-19 all kinds of special
subsidies received in the period
and tax reduction & exemption.Reversal of impairment reserve for account receivable with
separate impairment testing
378494.91
Consigning fee received for consigned operation 961488.75
Other non-operating income and expenditure except for the
aforementioned items
-11989346.42
Gains/losses items qualified definition of the non-recurring
gains/losses
955958.26
Less: impact on income tax 7360561.86
Impact on minority shareholders’ equity (post-tax) 9667131.04
Total 16257273.83 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss explain reasons
□ Applicable √ Not applicable
In reporting period the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss.II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
Total common shareholders at the
end of report period 34927
Total preference shareholders
with voting rights recovered at
end of reporting period (if
applicable)
0
Top ten shareholders
Shareholders
Nature of
shareholder
Proportion of
shares held
Amount of shares
held
Amount of
restricted shares
held
Number of share pledged/frozen
State of share Amount
Sinopharm Group
Co. Ltd.
State-owned
corporate
56.06% 239999991 5505770
FIRST SENTIER
INVESTORS
GLOBAL
UMBRELLA
FUND PLC -
FSSACHINA
GROWTH
FUND
Overseas
corporate 2.68% 11469644
Shanghai Gaoyi
Asset
Management
Partnership
(Limited
Partnership)-Gao
yi Linshan No. 1
Yuanwang Fund
Domestic non
state-owned
corporate
2.34% 10000000
Hong Kong
Securities
Clearing
Company Ltd.
Overseas
corporate 2.15% 9199504
National Social
Security Fund
118 Portfolio
Domestic non
state-owned
corporate
1.59% 6791699
China National
Pharmaceutical
Foreign Trade
State-owned
corporate 1.24% 5323043
Corp.
Central Huijin
Investment Ltd.State-owned
corporate 0.89% 3804400
Industrial and
Commercial
Bank of
China-Guangfa
Steady Growth
Securities
Investment Fund
Domestic non
state-owned
corporate
0.89% 3802617
BBH BOS S/A
FIDELITY FD -
CHINA FOCUS
FD
Overseas
corporate 0.78% 3358761
National Social
Security Fund
115 Portfolio
Domestic non
state-owned
corporate
0.78% 3333913
Particular about top ten shareholders with un-restrict shares held
Shareholders Amount of un-restrict shares held
Type of shares
Type Amount
Sinopharm Group Co. Ltd. 234494221
RMB ordinary
shares
234494221
FIRST SENTIER INVESTORS
GLOBAL UMBRELLA FUND PLC
- FSSA CHINAGROWTH FUND
11469644
Domestically
listed foreign
shares
11469644
Shanghai Gaoyi Asset Management
Partnership (Limited
Partnership)-Gaoyi Linshan No. 1
Yuanwang Fund
10000000
RMB ordinary
shares
10000000
Hong Kong Securities Clearing
Company Ltd. 9199504
RMB ordinary
shares
9199504
National Social Security Fund 118
Portfolio
6791699
RMB ordinary
shares
6791699
China National Pharmaceutical
Foreign Trade Corp. 5323043
RMB ordinary
shares
5323043
Central Huijin Investment Ltd. 3804400
RMB ordinary
shares
3804400
Industrial and Commercial Bank of
China-Guangfa Steady Growth
Securities Investment Fund
3802617
RMB ordinary
shares
3802617
BBH BOS S/A FIDELITY FD -
CHINA FOCUS FD
3358761
Domestically
listed foreign
shares
3358761
National Social Security Fund 115
Portfolio
3333913
RMB ordinary
shares
3333913
Explanation on associated
relationship among the aforesaid
shareholders
Sinopharm Group Co. Ltd. and China National Pharmaceutical Foreign Trade Corporation
have the same actual controller which is China National Pharmaceutical Group Corporation.It is unknown that there exists no associated relationship or belongs to the consistent actionist
among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Notes receivable had a decrease of 276.5989 million yuan from the beginning of the period with a growth rate
of -34.87% mainly due to changes in the procurement mode of hospital customers and changes in settlement
methods caused by the GPO policy;
2. Accounts receivable had an increase of 5446.291 million yuan from the beginning of the period with a growth
rate of 50.84% mainly due to the increase in days of turnover of accounts receivable caused by impact of the
COVID-19 outbreak and market environment and also the increase in accounts receivable at the end of the period
brought about by the newly merged company;
3. Receivable financing had an increase of 168.1186 million yuan from the beginning of the period with a growth
rate of 37.67% mainly due to changes in settlement methods with customers and the increase in financing of
accounts receivable at the end of the period brought about by the newly merged company;
4. Advances to suppliers had an increase of 138.3328 million yuan from the beginning of the period with a
growth rate of 35.49% mainly due to the increase in prepayments as the import letters of credit expired;
5. Dividend receivable had a decrease of 0.8349 million yuan from the beginning of the period with a growth rate
of -100% mainly because Shanghai Dingqun Enterprise Management Consulting Co. Ltd. has been included in
the scope of consolidation in the current period for the dividends receivable of the same period last year there is
no more balance at the consolidation level after internal offset;
6. Other current assets had a decrease of 32.7243 million yuan from the beginning of the period with a growth
rate of -32.02% mainly due to the decrease in the input tax to be deducted for value-added tax;
7. Intangible assets had an increase of 373.8836 million yuan from the beginning of the period with a growth rate
of 99.76% mainly due to the sales network generated by the acquisition of Shanghai Dingqun Enterprise
Management Consulting Co. Ltd. by the subsidiary Guoda Drug Store in the current period;
8. Goodwill had an increase of 1736.49 million yuan from the beginning of the period with a growth rate of
171.92% mainly due to the acquisition of Chengda Fangyuan Pharmaceutical Group Co. Ltd. and Shanghai
Dingqun Enterprise Management Consulting Co. Ltd. by the subsidiary Guoda Drug Store in the current period;
9. Deferred tax assets had an increase of 35.4016 million yuan from the beginning of the period with a growth
rate of 56.09% mainly due to the increase in the ending balance brought about by the newly merged companies in
the current period;
10. Other non-current assets had an increase of 195.5173 million yuan from the beginning of the period with a
growth rate of 252.75% mainly due to the procurement of emergency special reserve materials for the prevention
and control of the COVID-19 outbreak at the request of the government;
11. Short-term borrowings had an increase of 1770.8543 million yuan from the beginning of the period with a
growth rate of 121.87% mainly due to the increase in supply chain financing in the current period and the
increase in the ending short-term loans brought about by the newly merged companies;
12. Accounts payable had an increase of 3488.0446 million from the beginning of the period with a growth rate
of 52.03% mainly because the number of days for settlement of accounts payable has increased due to the impact
of the COVID-19 outbreak and the ending accounts payable brought about by the newly merged companies have
increased;
13. Interest payable had a decrease of 9.5779 million yuan from the beginning of the period with a growth rate of
-40.53% mainly due to the scheduled payment of factoring interest on accounts receivable;
14. Long-term borrowings had an increase of 31.6338 million yuan from the beginning of the period with a
growth rate of 100.00% mainly due to the loan received from Sinopharm Finance Company entrusted by China
National Pharmaceutical Group Corporation in the period;
15. Long-term payable had an increase of 6.1382 million yuan from the beginning of the period with a growth
rate of 767.27% mainly due to the increase in the ending balance brought about by the newly merged companies
in the current period;
16. Provisions had an increase of 67.7774 million yuan from the beginning of the period with a growth rate of
100.00% mainly due to the increase of the ending balance caused by new enterprise incorporated in current
period;
17. Deferred tax liabilities had an increase of 90.3191 million yuan from the beginning of the period with a
growth rate of 76.36% mainly due to the acquisition of Shanghai Dingqun Enterprise Management Consulting
Co. Ltd. by the subsidiary Guoda Drug Store in the current period resulting in deferred income tax liabilities
recognized by the asset fair assessment and appreciation；
18. Other non-current liabilities had an increase of 463.1607 million yuan from the beginning of the period with a
growth rate of 632.25% mainly due to the advance purchase of government emergency reserve materials for the
prevention and control of the COVID-19 outbreak;
19. Other incomes had a year-on-year increase of 17.58 million yuan with a growth rate of 61.45% mainly
because various special subsidies and tax reductions received in this period have increased due to the impact of
the COVID-19 outbreak;
20. Credit impairment losses had a year-on-year increase of 14.4377 million yuan with a growth rate of 98.58%
mainly due to the expansion of sales volume the increase in ending accounts receivable compared with the same
period last year and the number of days of accounts receivable turnover has increased due to the impact of the
new crown pneumonia epidemic so the provision for bad debts has increased accordingly;
21. Impairment losses had a year-on-year increase of 4.7512 million yuan with a growth rate of 571.45% mainly
due to the increase in the provision for inventory depreciation in the current period;
22. Gain on disposal of assets had a year-on-year increase of 6.7387 million yuan with a growth rate of
1153.53% mainly due to the loss resulting from lease cancellation incurred by the implementation of the new
lease standard for retail stores;
23. Non-operating income had a year-on-year increase of 2.8967 million yuanwith a growth rate of 42.09%
mainly due to the transfer of accounts payable that are not required to be paid into non-operating income during
the current period;
24. Non-operating expenses had a year-on-year increase of 18.0083 million yuan with a growth rate of 754.04%
mainly due to the provision of litigation compensation in the current period there was no such matter in the same
period last year;
25. Non-controlling interests had an increase of 59.1853 million yuan with a growth rate of 36.00% mainly due
to the acquisition of non-wholly-owned subsidiaries by the subsidiary Guoda Drug Store during the current period
which caused an increase in the profit and loss attributable to minority shareholders and an increase in the net
profit of Guoda Drug Store on a year-on-year basis and the minority shareholders' profit and loss attributable to
strategic investor Walgreens Boots Alliance (Hong Kong) Investments Limited (hereinafter referred to as "WBA")
increased accordingly;
26. Other comprehensive income net of tax had a year-on-year increase of 0.1439 million yuan with a growth
rate of 100.00% mainly due to the change of other equity from associated enterprise in the period;
27. Total comprehensive income attributable to non-controlling interests had a year-on-year increase of 59.1853
million yuan with a growth rate of 36.00% mainly due to the new acquisition of non-wholly-owned subsidiaries
by the subsidiary Guoda Drug Store during the current period which caused an increase in comprehensive income
attributable to minority shareholders and an increase in the net profit of Guoda Drug Store on a year-on-year basis
and the comprehensive income of minority shareholders attributable to WBA increased correspondingly;
28. Receipts of taxes and surcharges refunds had an increase of 7.2765 million yuan year-on-year with a growth
rate of 207.42% mainly due to the increase in tax refunds received in this period compared with the same period
last year;
29. Other cash receipts relating to operating activities had a year-on-year increase of 698.8992 million yuan with
a growth rate of 135.09% mainly due to the receipt of special reserve funds for the prevention and control of the
COVID-19 outbreak there was no such matter in the same period last year;
30. Cash payments related to other operating activities had a year-on-year increase of 259.1235 million yuan with
a growth rate of 32.11% mainly due to the year-on-year increase in various expenses and current accounts paid
during the current period;
31. Net cash flows from operating activities had a year-on-year increase of 924.5539 million yuan with a growth
rate of 87.32% mainly because the company has formulated stricter fund management plans increased the
collection of accounts receivable and effectively controlled purchase payments and received the emergency
special reserve funds for the prevention and control of the COVID-19 outbreak in the current period;
32. Cash receipts from returns of investments had a year-on-year increase of 19.0276 million yuan with a growth
rate of 100.00% because received the withdrawal of principal from the China National Zhongjin Medical Industry
Fund;
33. Cash receipts from returns on investments had a year-on-year increase of 81.3311 million yuan with a growth
rate of 103.95% because the cash dividends received from associates in the current period increased on a
year-on-year basis;
34. Cash receipts related to other investing activities had a year-on-year decrease of 346.5745 million yuan with a
growth rate of -94.02% because the consolidated subsidiary Pudong New Area of Shanghai Pharmaceutical
Medicine Co. Ltd. under the same control of the subsidiary Guoda Drug Store in the current period received the
funds allocated from the fund pool of its original parent company Sinopharm Group Co. Ltd. in the same period
of last year and the funds originally collected was taken back into the cash pool in this period;
35. Sub-total of cash inflows from investing activities had a year-on-year decrease of 245.9187 million yuan with
a growth rate of -54.43% mainly because the consolidated subsidiary Pudong New Area of Shanghai
Pharmaceutical Medicine Co. Ltd. under the same control of the subsidiary Guoda Drug Store in the current
period received the funds allocated from the fund pool of its original parent company Sinopharm Group Co. Ltd.in the same period of last year and the funds originally collected was taken back into the cash pool in this period;
36. Cash paid for acquisition of investments had a year-on-year decrease of 56.1288 million yuan with a growth
rate of -66.39% mainly due to the decrease in the store transfer fee paid by the subsidiary Guoda Drug Store for
the purchase of retail stores during the current period;
37. Net cash paid for acquisition of subsidiaries and other business units had an a year-on-year increase of
2379.2871 million yuan with a growth rate of 44656.29% mainly due to the net cash paid for the acquisition of
Chengda Fangyuan Pharmaceutical Group Co. Ltd. and Shanghai Dingqun Enterprise Management Consulting
Co. Ltd. by the subsidiary Guoda Drug Store there was no such matter in the same period last year;
38. Cash payments related to other investing activities had a year-on-year decrease of 340.7033 million yuan with
a growth rate of -98.55% mainly because the subsidiary Guoda Drug Store merged into Pudong New Area of
Shanghai Pharmaceutical Medicine Co. Ltd. under the same control during the current period and the fund pool
in the same period last year was collected to the original parent company Sinopharm Group Co. Ltd. there was
no such matter in this period;
39. Sub-total of cash outflows from investing activities had a year-on-year increase of 2004.8201 million yuan
with a growth rate of 332.98% mainly due to the net cash paid by the subsidiary Guoda Drug Store for the
acquisition of Chengda Fangyuan Pharmaceutical Group Co. Ltd. and Shanghai Dingqun Enterprise Management
Consulting Co. Ltd. in the current period there was no such matter in the same period last year;
40. Net cash flow from investing activities had a year-on-year decrease of 2250.7388 million yuan with a growth
rate of -1497.99% mainly due to the net cash paid by the subsidiary Guoda Drug Store for the acquisition of
Chengda Fangyuan Pharmaceutical Group Co. Ltd. and Shanghai Dingqun Enterprise Management Consulting
Co. Ltd. in the current period there was no such matter in the same period last year;
41. Cash proceeds from investments by others had a year-on-year decrease of 44.548 million yuan with a growth
rate of -100% mainly due to the receipt of capital increase from minority shareholders in the same period last year.There was no such matter in this period;
42. Cash received from borrowings had a year-on-year increase of 696.82 million yuan with a growth rate of
665.54% mainly due to the receipt of special loan funds for the prevention and control of the COVID-19 outbreak
in this period and the increase in bank loans;
43. Cash receipts related to other financing activities had a year-on-year increase of 317.677 million yuan with a
growth rate of 16145.16% mainly due to the receipt of loans from non-financial institutions in the current period
and the increase in the return of guarantee deposits for the draft received in the current period；
44. Sub-total of cash inflows from financing activities had a year-on-year increase of 969.949 million yuan with a
growth rate of 641.43% mainly due to the receipt of special loan funds for the prevention and control of the
COVID-19 outbreak in this period and the receipt of loans from non-financial institutions in this period；
45. Cash repayments for debts had a year-on-year increase of 152.1929 million yuan with a growth rate of
94.35% mainly due to the increase in loan repayments during the current period;
46. Cash payments related to other financing activities had a year-on-year increase of 1056.3758 million yuan
with a growth rate of 174.70% mainly due to the repayment of loans from non-financial institutions during the
current period and the increase in rental payments in retail stores;
47. Sub-total of cash outflows from financing activities had a year-on-year increase of 1301.6337 million yuan
with a growth rate of 106.79% mainly due to the repayment of loans from non-financial institutions in the current
period and the increase in rent paid by retail stores;
48. Net cash flow from financing activities had a year-on-year decrease of 331.6847 million yuan with a growth
rate of -31.07% mainly due to the year-on-year increase in rent paid by retail stores and the investment funds
paid by the subsidiary Guoda Drug Store for the consolidation of the subsidiary Pudong New Area of Shanghai
Pharmaceutical Medicine Co. Ltd. under the same control in the current period;
49. Effect of foreign exchange rate changes on cash and cash equivalents had a year-on-year increase of 0.1259
million yuan with a growth rate of 71.52% mainly due to the impact of exchange rate changes;
50. Net increase in cash and cash equivalents had a year-on-year decrease of 1657.7437 million yuan with a
growth rate of -1040.83% mainly due to the investment paid by the subsidiary Guoda Drug Store for the
acquisition of Chengda Fangyuan Pharmaceutical Group Co. Ltd. and Shanghai Dingqun Enterprise Management
Consulting Co. Ltd. during the current period. There was no such matter in the same period last year.
II. Progress and influence of the main events as well as solution analysis specification
□Applicable √ Not applicable
Progress of shares buy-back
□Applicable √Not applicable
Implementation progress of the reduction of repurchases shares by centralized bidding
□Applicable √Not applicable
III. Commitments that the company shareholders actual controller offeror directors
supervisors senior management or other related parties have fulfilled during the reporting
period and have not yet fulfilled by the end of reporting period
□Applicable √ Not applicable
There are no commitments that the company shareholders actual controller offeror directors supervisors senior management or
other related parties have fulfilled during the reporting period and have not yet fulfilled by the end of reporting period.IV. Financial asset investment
1. Particular about security investment
□Applicable √ Not applicable
The Company had no security investment in Period.
2. Particulars about derivatives investment
□Applicable √ Not applicable
The Company had no derivatives investment in Period.V. Progress of investment projects with raised funds
□Applicable √ Not applicable
VI. Prediction of 2020 business performance
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the
warning of its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
VII. Major contracts for daily operations
□Applicable √ Not applicable
VIII. Trust financing
□Applicable √ Not applicable
The Company had no trust financing in Period.IX. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the reporting period.X. Non-operational fund occupation from controlling shareholders and its related party
□Applicable √ Not applicable
The Company had no non-operational fund occupation from controlling shareholders and its related party.XI. Registration form for receiving research communication and interview in the report
period
□Applicable √Not applicable
The Company had no receiving research communication or interview in the report period.Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2020-09-30
In RMB
Item 2020-9-30 2019-12-31
Current assets:
Cash and bank balances 6962649007.83 8885729250.47
Settlement provisions
Capital lent
Tradable financial assets
Derivative financial assets
Notes receivable 516702799.00 793301688.64
Accounts receivable 16159274568.20 10712983544.18
Receivable financing 614461184.65 446342588.46
Advances to suppliers 528161580.38 389828785.54
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Other receivables 625955680.32 501958841.43
Including: Interest receivable
Dividend receivable 834914.61
Buying back the sale of financial
assets
Inventories 6472039528.37 5063274143.26
Contractual assets
Assets held for sale
Non-current asset due within one
year
Other current assets 69483189.74 102207498.20
Total current assets 31948727538.49 26895626340.18
Non-current assets:
Loans and payments on behalf
Debt investment
Other debt investment
Long-term account receivable
Long-term equity investment 2180792355.94 2105114410.88
Other equity instruments
investment 116021000.00 116021000.00
Other non-current financial assets 120972350.24 140000000.00
Investment properties 129386716.54 138900358.30
Fixed assets 830176528.72 708000172.63
Construction in progress 34002571.84 31582575.84
Productive biological asset
Oil and gas asset
Right-of-use assets 2364186871.11 1994757862.07
Intangible assets 748672438.97 374788799.48
Expense on Research and
Development
Goodwill 2746547971.28 1010057927.17
Long-term prepaid expenses 422329641.93 373527968.14
Deferred tax assets 98512476.79 63110829.12
Other non-current assets 272872270.66 77354970.39
Total non-current assets 10064473194.02 7133216874.02
Total assets 42013200732.51 34028843214.20
Current liabilities:
Short-term borrowings 3223872627.85 1453018300.01
Loan from central bank
Capital borrowed
Trading financial liability
Derivative financial liability
Notes payable 6517277316.76 5555697557.53
Accounts payable 10192012474.51 6703967826.54
Accounts received in advance
Contract liabilities 319872358.57 303194940.70
Selling financial asset of
repurchase
Absorbing deposit and interbank
deposit
Security trading of agency
Security sales of agency
Employee benefits payable 297011161.64 259640813.10
Tax payable 266341378.00 253379524.34
Other payables 1819483384.19 1822364637.62
Including: Interest payable 14054694.93 23632632.90
Dividend payable 6389320.96 6389320.96
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within
one year 722848572.29 611917847.37
Other current liabilities 888938.88 749710.19
Total current liabilities 23359608212.69 16963931157.40
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 31633794.44
Bonds payable
Including: Preferred stock
Perpetual capital
securities
Lease liabilities 1315854064.33 1208453029.51
Long-term payable 6938189.00 800000.00
Long-term employee benefits
payable 1390000.00 1433000.00
Provisions 67777417.09
Deferred income 86200079.36 88704272.88
Deferred tax liabilities 208604078.87 118284962.77
Other non-current liabilities 536417234.89 73256514.93
Total non-current liabilities 2254814857.98 1490931780.09
Total liabilities 25614423070.67 18454862937.49
Owner’s equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: Preferred stock
Perpetual capital
securities
Capital surplus 4372924761.28 4470766959.44
Less: Inventory shares
Other comprehensive income 46061282.19 45917342.77
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Provision of general risk
Retained earnings 8492975215.79 7752265659.17
Shareholders’ equity attributable to
shareholders of the parent 13554151733.76 12911140435.88
Non-controlling interests 2844625928.08 2662839840.83
Total shareholders’ equity 16398777661.84 15573980276.71
Total liabilities and shareholders’ equity 42013200732.51 34028843214.20
Legal Representative: Lin Zhaoxiong
Accounting Principal: Gu Guolin
Accounting Firm’s Principal: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item 2020-9-30 2019-12-31
Current assets:
Cash and bank balances 3623472432.84 2909417289.71
Trading financial assets
Derivative financial assets
Notes receivable 14900068.42
Accounts receivable 825123171.17 571544784.65
Receivable financing 14286247.98 30194682.11
Advances to suppliers 2255341.39 7996243.28
Other receivables 2238224576.05 1928941595.38
Including: Interest receivable
Dividend receivable 834914.61
Inventories 180659951.37 169422075.78
Contractual assets
Assets held for sale
Non-current assets maturing within
one year
Other current assets 39482.38 39482.38
Total current assets 6884061203.18 5632456221.71
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investments 7768347868.17 7698756525.83
Investment in other equity
instrument
Other non-current financial assets 120972350.24 140000000.00
Investment properties 1460148.67 1484198.56
Fixed assets 14313510.88 14763656.62
Construction in progress
Productive biological assets
Oil and natural gas assets
Right-of-use assets 5428250.46 6217504.50
Intangible assets 4968294.45 5838737.17
Research and development costs
Goodwill
Long-term prepaid expenses 4688164.95 6130534.55
Deferred tax assets 9314310.47 9327850.53
Other non-current assets 12442236.49 9000000.00
Total non-current assets 7941935134.78 7891519007.76
Total assets 14825996337.96 13523975229.47
Current liabilities
Short-term borrowings 247722171.73 121350644.36
Trading financial liability
Derivative financial liability
Notes payable 577672670.63 751577900.22
Accounts payable 604053901.91 322436681.01
Accounts received in advance
Contract liabilities 24386087.49 7293184.46
Employee benefits payable 32139686.65 30469777.88
Taxes payable 16082246.01 22909124.90
Other payables 2505736963.13 2120794765.05
Including: Interest payable 358968.22 861110.53
Dividend payable
Liability held for sale
Non-current liabilities due within
one year 1044745.35 32640325.77
Other current liabilities 220070.94 338196.81
Total current liabilities 4009058543.84 3409810600.46
Non-current liabilities:
Long-term borrowings 31633794.44
Bonds payable
Including: preferred stock
Perpetual capital
securities
Lease liabilities 4723839.22 5461257.38
Long-term payable 800000.00 800000.00
Long-term employee benefits
payable 21000.00
Accrued liabilities
Deferred income 939918.30 1276698.66
Deferred income tax liabilities
Other non-current liabilities 6750487.95
Total non-current liabilities 44869039.91 7537956.04
Total liabilities 4053927583.75 3417348556.50
Owners’ equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital surplus 4468412139.15 4468385307.32
Less: Inventory shares
Other comprehensive income 10573.23 -133366.19
Special reserve
Surplus reserve 214063491.50 214063491.50
Retained earnings 5661455567.33 4996184257.34
Total owner’s equity 10772068754.21 10106626672.97
Total liabilities and owner’s equity 14825996337.96 13523975229.47
3. Consolidated Profit Statement (the period)
In RMB
Item Current period Last period
I. Total operating revenue 15710564937.11 13824236956.99
Including: Operating revenue 15710564937.11 13824236956.99
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating costs 15303846841.06 13468651756.73
Including: Operating costs 13973474907.40 12397323704.29
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 40704486.64 36849813.53
Selling expenses 1021255859.95 789902994.19
Administrative expense 247039895.13 215510730.76
R&D expense
Finance costs 21371691.94 29064513.96
Including: Interest cost 69345341.35 73519643.35
Interest income 47423651.34 42782208.81
Add: other incomes 10332398.22 12116753.12
Investment income (Loss is
listed with “-”) 106744145.25 69951393.31
Including: Investment income
from associates 113954215.33 86019936.49
Income from the
derecognition of financial assets
measured at amortised cost (Loss is listed
with “-”)
-7260070.08 -16118543.18
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Credit impairment losses (Loss
is listed with “-”) -7503494.54 -3211918.65
Impairment losses (Loss is
listed with “-”) -3838776.90 -705879.81
Gain on disposal of assets
(Loss is listed with “-”) 3017582.41 613909.71
III. Operating profit (Loss is listed with
“-”) 515469950.49 434349457.94
Add: Non-operating income 4558551.96 3208143.43
Less: Non-operating expenses 17387648.55 638789.06
IV. Total profit (Loss is listed with “-”) 502640853.90 436918812.31
Less: Income taxes 87693175.37 80186257.89
V. Net profit (Net loss is listed with “-”) 414947678.53 356732554.42
(i) Classify by business continuity
1. profit or loss from continuingoperations (net loss listed with ‘-”) 414947678.53 356732554.42
2.termination of net profit (net losslisted with ‘-”)
(ii) Classify by ownership
1. Owners of the parent 354134165.83 310253592.48
2. Non-controlling interests 60813512.70 46478961.94
VI. Other comprehensive income net of
tax 21752.53
Other comprehensive income
attributable to shareholders of owners of
the parent net of tax
21752.53
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
that may be reclassified to profit or loss 21752.53
1. Other comprehensive
income using the equity method that may
be reclassified to profit or loss
21752.53
2.Change of fair value of
other debt investment
3.Amount of financial assets
re-classify to other comprehensive
income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging reserve
6.Translation differences
arising on translation of foreign currency
financial statements
7.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 414969431.06 356732554.42
Total comprehensive income
attributable to shareholders of the parent 354155918.36 310253592.48
Total comprehensive income
attributable to non-controlling interests 60813512.70 46478961.94
VIII. Earnings per share:
(i) Basic earnings per share 0.83 0.72
(ii) Diluted earnings per share 0.83 0.72
Enterprise combine under the same control in the Period the combined party realized net profit of 0.00 Yuan before combination and
realized -2559759.75 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Accounting Principal: Gu Guolin
Accounting Firm’s Principal: Wang Ying
4. Profit Statement of Parent Company (the period)
In RMB
Item Current period Last period
I. Operating revenue 1045312749.83 1112624846.96
Less: Operating cost 998626282.80 1064701021.03
Taxes and surcharge 1971974.46 1964184.59
Sales expenses 16645559.49 17984619.36
Administration expenses 21487255.62 24299300.83
R&D expenses
Finance costs -19457068.52 -12688664.89
Including: Interest cost 12460526.51 14404910.73
Interest income 32385886.23 27695670.05
Add: other income 132260.12 219828.06
Investment income (Loss is
listed with “-”) 113805608.42 472311092.78
Including: Investment income
from associates 113923021.39 91259842.03
Income from the
derecognition of financial assets
measured at amortized cost (Loss is
-117412.97 -1201462.13
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Credit impairment losses
(Loss is listed with “-”) -161522.25
Impairment loss (Loss is
listed with “-”) -477234.68 -234019.78
Gain on disposal of assets
(Loss is listed with “-”) -165.97 181433.34
II. Operating profit (Loss is listed with
“-”) 139499213.87 488681198.19
Add: Non-operating income 237.88 373.35
Less: Non-operating expense 0.02
III. Total Profit (Loss is listed with “-”) 139499451.73 488681571.54
Less: Income taxes 6442994.33 3675740.93
IV. Net profit (Net loss is listed with
“-”) 133056457.40 485005830.61
(i) profit or loss from continuingoperations (net loss listed with ‘-”) 133056457.40 485005830.61
(ii) termination of net profit (netloss listed with ‘-”)
V. Other comprehensive income net of
tax 21752.53
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income 21752.53
that may be reclassified to profit or loss
1. Other comprehensive
income using the equity method that
may be reclassified to profit or loss
21752.53
2.Change of fair value of
other debt investment
3.Amount of financial
assets re-classify to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6.Translation differences
arising on translation of foreign
currency financial statements
7.Other
VI. Total comprehensive income 133078209.93 485005830.61
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Profit Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Total operating revenue 42880505125.63 39423435772.29
Including: Operating revenue 42880505125.63 39423435772.29
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating costs 41581721662.96 38242360900.06
Including: Operating costs 37944504626.84 35110200308.48
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 110209795.96 99561207.90
Selling expenses 2749994678.55 2331188042.13
Administrative expenses 690327040.05 607359068.67
R&D expense
Finance costs 86685521.56 94052272.88
Including: Interest cost 202695852.03 208314880.76
Interest income 112936201.56 103423311.30
Add: other income 46187696.54 28607672.14
Investment income (Loss is
listed with “-”) 211950494.51 196824879.75
Including: Investment income
from associates 247559119.49 255162226.48
Income from the
derecognition of financial assets
measured at amortized cost (Loss is listed
with “-”)
-40767172.72 -58387346.73
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Credit impairment losses (Loss
is listed with “-”) -29083726.06 -14646019.78
Impairment losses (Loss is
listed with “-”) -5582665.20 -831434.15
Gain on disposal of assets
(Loss is listed with “-”) 7322907.21 584184.27
III. Operating profit (Loss is listed with
“-”) 1529578169.67 1391614154.46
Add: Non-operating income 9778532.18 6881835.88
Less: Non-operating expense 20396541.07 2388239.14
IV. Total profit (Loss is listed with “-”) 1518960160.78 1396107751.20
Less: Income taxes 297799939.72 272310616.73
V. Net profit (Net loss is listed with “-”) 1221160221.06 1123797134.47
(i) Classify by business continuity
1. profit or loss from continuingoperations (net loss listed with ‘-”) 1221160221.06 1123797134.47
2.termination of net profit (net losslisted with ‘-”)
(ii) Classify by ownership
1.Owners of the parent 997585746.42 959408007.03
2.Non-controlling interests 223574474.64 164389127.44
VI. Other comprehensive income net of
tax 143939.42
Other comprehensive income
attributable to shareholders of owners of
the parent net of tax
143939.42
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
that may be reclassified to profit or loss 143939.42
1. Other comprehensive
income using the equity method that may
be reclassified to profit or loss
143939.42
2.Change of fair value of
other debt investment
3.Amount of financial assets
re-classify to other comprehensive
income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging reserve
6.Translation differences
arising on translation of foreign currency
financial statements
7.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 1221304160.48 1123797134.47
Total comprehensive income
attributable to shareholders of the parent 997729685.84 959408007.03
Total comprehensive income
attributable to non-controlling interests 223574474.64 164389127.44
VIII. Earnings per share:
(i) Basic earnings per share 2.33 2.24
(ii) Diluted earnings per share 2.33 2.24
Enterprise combine under the same control in the Period the combined party realized net profit of 0.00 Yuan before combination and
realized -3587735.01 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Accounting Principal: Gu Guolin
Accounting Firm’s Principal: Wang Ying
6. Profit Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Operating revenue 2817800113.39 3120629410.26
Less: Operating costs 2688190345.04 2985973415.79
Taxes and surcharge 4554615.32 4483432.58
Selling expenses 48021936.53 49036664.17
Administration expenses 64547735.37 62356107.14
R&D expenses
Finance costs -63295185.86 -43265784.17
Including: interest expenses 34388587.85 35792756.82
Interest income 98955206.08 80175392.47
Add: other income 762181.59 552592.19
Investment income (Loss is
listed with “-”) 863439369.20 1078420637.97
Including: Investment income
from associates 247472516.77 272540375.14
Income from the
derecognition of financial assets
measured at amortised cost (Loss is
listed with “-”)
-1644381.22 -3380337.41
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Credit impairment losses
(Loss is listed with “-”) -976022.96 -2527287.33
Impairment loss (Loss is
listed with “-”) -719966.55 -336132.62
Gain on disposal of assets
(Loss is listed with “-”) -165.97 155358.82
II. Operating profit (Loss is listed with
“-”) 938286062.30 1138310743.78
Add: Non-operating income 1834.65 46442.75
Less: Non-operating expense 52122.74
III. Total Profit (Loss is listed with “-”) 938235774.21 1138357186.53
Less: Income taxes 16088274.42 12674965.45
IV. Net profit (Net loss is listed with
“-”) 922147499.79 1125682221.08
(i) profit or loss from continuingoperations (net loss listed with ‘-”) 922147499.79 1125682221.08
(ii) termination of net profit (netloss listed with ‘-”)
V. Other comprehensive income net of
tax 143939.42
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income
that may be reclassified to profit or loss 143939.42
1. Other comprehensive
income using the equity method that
may be reclassified to profit or loss
143939.42
2.Change of fair value of
other debt investment
3.Amount of financial
assets re-classify to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6.Translation differences
arising on translation of foreign
currency financial statements
7.Other
VI. Total comprehensive income 922291439.21 1125682221.08
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
7. Consolidated Cash Flow Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from sales of good 42418077097.10 40055008686.20
or rendering of services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings
and investment
Cash received from interest
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Net cash received by agents in sale
and purchase of securities
Receipts of taxes and surcharges
refunds 10784614.07 3508074.72
Other cash receipts relating to
operating activities 1216248037.55 517348861.84
Sub-total of cash inflows from
operating activities 43645109748.72 40575865622.76
Cash paid for goods and services 37533521802.87 36077610134.36
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Net increase of capital lent
Cash paid for interest commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to and on behalf of
employees 1913705773.98 1672811261.76
Cash paid for all types of taxes 1148433266.37 959672684.15
Cash payments related to other
operating activities 1066101719.26 806978262.18
Sub-total of cash outflows from
operating activities 41661762562.48 39517072342.45
Net cash flows from operating activities 1983347186.24 1058793280.31
II. Cash flows arising from investing
activities:
Cash receipts from returns of inves
tments 19027649.76
Cash receipts from returns on inve
stments 159574046.42 78242963.78
Net cash received from disposal of
fixed assets intangible assets and other
long-term assets
5274705.47 4977626.76
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
investing activities 22040000.00 368614498.90
Subtotal of cash inflow from investing
activities 205916401.65 451835089.44
Cash paid for acquisition of fixed
assets intangible assets and other
long-term assets
188880164.05 166514970.91
Cash paid for acquisition of
investments 28410468.41 84539317.61
Net increase of mortgaged loans
Net cash paid for acquisition of
subsidiaries and other business units 2384615064.76 5328000.00
Cash payments related to other
investing activities 5000000.00 345703306.28
Subtotal of cash outflow from investing
activities 2606905697.22 602085594.80
Net cash flows from investing activities -2400989295.57 -150250505.36
III. Cash flows arising from financing
activities
Cash proceeds from investments
by others 44548000.00
Incl: Cash proceeds from
subsidiary investments by
non-controlling shareholders
44548000.00
Cash received from borrowings 801520037.57 104700000.00
Cash receipts related to other
financing activities 319644627.50 1967629.61
Sub-total of cash inflows from
financing activities 1121164665.07 151215629.61
Cash repayments for debts 313500000.00 161307142.79
Cash payments for distribution of
dividends or profit and interest
expenses
545931923.60 452866856.35
Incl: Profit and dividends paid to
non-controlling shareholders of
subsidiaries
62338791.80 28493123.11
Cash payments related to other
financing activities 1661056163.63 604680365.03
Subtotal of cash outflow from financing
activities 2520488087.23 1218854364.17
Net cash flows from financing activities -1399323422.16 -1067638734.56
IV. Effect of foreign exchange rate
changes on cash and cash equivalents -50126.70 -175994.42
V. Net increase of cash and cash
equivalents -1817015658.19 -159271954.03
Add: Cash and cash equivalents at
beginning of the year 8426071170.16 7634936037.30
VI. Cash and cash equivalents at end of
year 6609055511.97 7475664083.27
8. Cash Flow Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current period Last period
I. Cash flows arising from operating
activities:
Cash received from sales of good
or rendering of services 2801262096.63 3217890947.38
Write-back of tax received
Other cash receipts relating to
operating activities 118590737.66 32674054.58
Sub-total of cash inflows from
operating activities 2919852834.29 3250565001.96
Cash paid for goods and services 2670157831.18 3191926190.64
Cash paid to and on behalf of
employees 77688934.66 73601798.69
Cash paid for all types of taxes 61976566.00 43156828.71
Cash payments related to other
operating activities 39479023.87 24724274.57
Sub-total of cash outflows from
operating activities 2849302355.71 3333409092.61
Net cash flows from operating activities 70550478.58 -82844090.65
II. Cash flows arising from investing
activities:
Cash receipts from returns of inves
tments 32664096.76
Cash receipts from returns on inve
stments 333064697.85 619976538.54
Net cash received from disposal of
fixed assets intangible assets and other
long-term assets
2900.00 3961383.00
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
investing activities 1996202038.52 1482390000.00
Sub-total of cash inflow from investing
activities 2361933733.13 2106327921.54
Cash paid for acquisition of fixed
assets intangible assets and other
long-term assets
11926875.85 6777035.03
Cash paid for acquisition of
investments 19998000.00
Net cash received from
subsidiaries and other units obtained
Cash payments related to other
investing activities 2296122707.02 1812850181.28
Sub-total of cash outflows from
investing activities 2308049582.87 1839625216.31
Net cash flows from investing activities 53884150.26 266702705.23
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from borrowings 63864821.52 10000000.00
Cash receipts related to other
financing activities 24518926964.22 18437509464.22
Sub-total of cash inflow from financing
activities 24582791785.74 18447509464.22
Cash repayments for debts 43700000.00 10000000.00
Cash payments for distribution of
dividends profit or interest expenses 285557151.27 191576803.94
Cash payments related to other
financing activities 23660780660.15 17703057206.85
Sub-total of cash outflow from
financing activities 23990037811.42 17904634010.79
Net cash flows from financing activities 592753974.32 542875453.43
IV. Effect of foreign exchange rate
changes on cash and cash equivalents -50126.70 -175994.42
V. Net increase of cash and cash
equivalents 717138476.46 726558073.59
Add: Cash and cash equivalents at
beginning of the year 2894333956.38 1817654598.01
VI. Cash and cash equivalents at end of
year 3611472432.84 2544212671.60
II. Explanation on financial statement adjustment
1. Financial statement adjustment at the beginning of the first year when implementation of new revenue
rules and new leasing rules from 2020
□Applicable √Not applicable
2. Retrospective adjustment of the comparative data for initial implementation of new revenue rules and
new leasing rules from 2020
□Applicable √Not applicable
III. Audit report
Whether the 3rd quarterly report has been audited or not
□Yes √ No
3Q report of the Company is unaudited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
October 22 2020
沪公网安备31011802005267号
